Journal: Diabetes, Metabolic Syndrome and Obesity
Article Title: Fu-Fang-Qi-Di-Hua-Yu-Tang Improves Diabetic Macrovascular Disease via PI3K/AKT Pathway Regulation
doi: 10.2147/DMSO.S515521
Figure Lengend Snippet: Comparison of protein expression via the RAGE/PI3K/AKT/mTOR pathway among different groups. ( a ) Electrophoresis of protein expression A. Control group; B. Model group; C. L-FFQD group; D. M-FFQD group; E. H-FFQD group; F. ATOR-MAT group); ( b ) Relative value of RAGE; ( c ) Relative value of P-PI3K/PI3K; ( d ) Relative value of P-AKT/AKT; ( e ) Relative value of LC3II/I; ( f ) Relative value of P62; ( g ) Relative value of NF-κB p65; ( h ) Relative value of P-mTOR/mTOR. Compared with the control (** P< 0.01), model ( # P< 0.05, ## P< 0.01), L-FFQD ( ◆ P< 0.05, ◆◆ P< 0.01), M-FFQD ( ΔΔ P< 0.01), and H-FFQD ( ★ P< 0.05, ★★ P< 0.01) groups, significant differences were observed.
Article Snippet: The membrane was then incubated overnight at 4°C with primary antibodies: LC3-II/I (18725-1-AP, Proteintech, USA), NF-κB p65 (10,745-1-AP, Proteintech, USA) (1:500), RAP1 (10,840-1-AP, Proteintech, USA), PI3K (20584-1-AP, Proteintech, USA), P-PI3K (bs-6417R, Bioss, China), mTOR (#2983, CST, USA) (1:1000), P-mTOR (67778-1-Ig, Proteintech, USA) (1:2000), RAGE (16346-1-AP, Proteintech, USA), P-AKT (66444-1-Ig, Proteintech, USA) (1:3000), P62 (18,420-1-AP, Proteintech, USA), AKT (60203-2-Ig, Proteintech, USA), FOX01 (18,592-1-AP, Proteintech, USA), β-actin (66009-1-Ig, Proteintech, USA), and GAPDH (10494-1-AP, Proteintech, USA) (1:5000) antibodies.
Techniques: Comparison, Expressing, Electrophoresis, Control